QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$5.90
+82.1%
$5.59
$2.70
$44.80
$4.01M0.35982,676 shs72.89 million shs
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$0.48
$0.31
$10.10
$6.88M4.16713,628 shsN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.06
-10.2%
$1.82
$1.03
$9.38
$488K11.06 million shs688,771 shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+6.95%-6.65%-33.54%-61.54%-88.38%
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-27.16%-28.48%-29.34%-32.95%-80.33%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1.4633 of 5 stars
3.52.00.00.02.90.00.6
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$40.00577.97% Upside
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest MLNT, BPTH, SXTC, and TRLPF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $40.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$96.43M0.00N/AN/A$16.96 per share0.00
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.97M0.25N/AN/A$32.12 per share0.03
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
-$157.19M-$17.72N/AN/AN/A-393.39%-101.29%-28.68%N/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$5.93MN/A0.00N/AN/AN/AN/A7/29/2024 (Estimated)
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A

Latest MLNT, BPTH, SXTC, and TRLPF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/8/202412/31/2023
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$5.40-$5.40N/AN/AN/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
1.60
1.60
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
1.11
1.03
0.72
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.02
1.47
1.41
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
18.02%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
5.02%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
10680,000658,000Optionable
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
29013.75 millionN/AOptionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
78460,000439,000Not Optionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

MLNT, BPTH, SXTC, and TRLPF Headlines

SourceHeadline
Takeda Pharmaceutical Co. Ltd. ADRTakeda Pharmaceutical Co. Ltd. ADR
wsj.com - February 8 at 10:03 AM
Other OTC Pharmaceuticals - LithuaniaOther OTC Pharmaceuticals - Lithuania
statista.com - September 17 at 1:59 AM
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
seekingalpha.com - January 1 at 9:14 AM
Acerus Reports Second Quarter 2022 Financial ResultsAcerus Reports Second Quarter 2022 Financial Results
financialpost.com - August 9 at 7:47 AM
Acerus Reports Fourth Quarter and Full Year 2021 Financial ResultsAcerus Reports Fourth Quarter and Full Year 2021 Financial Results
financialpost.com - March 15 at 7:47 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bio-Path logo

Bio-Path

NASDAQ:BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Melinta Therapeutics logo

Melinta Therapeutics

NASDAQ:MLNT
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
China SXT Pharmaceuticals logo

China SXT Pharmaceuticals

NASDAQ:SXTC
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:TRLPF
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.